- Health resource utilization associated with skeletal-related events: results from a retrospective European study2016 | Faculty of Medicine in Pilsen
- Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic2017 | Publication without faculty affiliation
- Cost of skeletal complications from bone metastases in six European countries2016 | Publication without faculty affiliation
- Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup2014 | Publication without faculty affiliation
- Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study2018 | Publication without faculty affiliation
- Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries2016 | Publication without faculty affiliation
- Bone metastases in urology2011 | Third Faculty of Medicine
- Denosumab in patients with skeletal metastases2021 | Faculty of Medicine in Pilsen
- Denosumab - an important part of the treatment of patients with skeletal metastatic disease2020 | Faculty of Medicine in Pilsen
- Pembrolizumab: treatment in patients with axial skeletal metastases, after stabilization of the spine – case reports2023 | Third Faculty of Medicine, Central Library of Charles University, First Faculty of Medicine
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma2011 | Second Faculty of Medicine
- Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer The VIABLE Phase 3 Randomized Clinical Trial2022 | Faculty of Medicine in Hradec Králové